米氮平联合艾司西酞普兰治疗卒中后抑郁的临床疗效评价

Clinical evaluation of mirtazapine combined escitalopram on treating post-stroke depression

目的观察米氮平联合艾司西酞普兰治疗卒中后抑郁的临床效果。方法将符合卒中后抑郁症诊断的脑卒中患者98例随机分为两组,治疗组50例在常规药物治疗及康复训练的基础上加用米氮平联合艾司西酞普兰抗抑郁治疗,对照组48例单采用神经科常规药物治疗及康复训练,两组患者分别在入选时及病程1、3、6个月进行日常生活能力(BI)和汉密尔顿抑郁量表(HAMD)评分。结果治疗前两组BI、HAMD评分差异无统计学意义(P>0.05),治疗1、3、6个月后治疗组与对照组比较差异有统计学意义(P<0.05)。治疗组HAMD、BI评分于治疗3、6个月后显著改善(P<0.05)。结论米氮平联合艾司西酞普兰治疗卒中后抑郁具有显著临床疗效。患者抑郁症状改善的同时显著改善患者日常生活能力。

Objective To observe the clinical efficacy of mirtazapine combined escitalopram on treating post-stroke depression （PSD）. Methods 98 patients with PDS diagnosed by Hamilton Depression Rating Scale （HAMD） were randomly divided into observation group and control group, control group （50 cases） with mirtazapine combined escitalopram therapy based on standardized treatment of stroke and rehabilitation. The control group （48 cases） only with standardized treatment of stroke and rehabilitation. Two groups were evulated and compared using Hamilton Depression Rating Scale （HAMD） and Barthel Index （BI） and compared before and after 1, 3, 6 months of treatment. Results There was no significant difference in HAMA and BI in two groups before treatment, the study group reduced rate of HAMA and increase rate of BI higher than that control group after 1, 3, 6 months. The improvement of HAMD, BI was significant in the control group after1, 3, 6 months of treatment. Conclusions Mirtazapine combined escitalopram has significant clinical effect in treatment of post-stroke depression, which can improve depressive symptoms and patients’daily life at the same time.